These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 2482453)

  • 21. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
    Sheu JR; Fu CC; Tsai ML; Chung WJ
    Anticancer Res; 1998; 18(6A):4435-41. PubMed ID: 9891506
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Human three-dimensional fibroblast cultures express angiogenic activity.
    Pinney E; Liu K; Sheeman B; Mansbridge J
    J Cell Physiol; 2000 Apr; 183(1):74-82. PubMed ID: 10699968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of the VEGF, bFGF, aFGF and IL8 angiogenic activity in urinary bladder carcinoma, using the mice cutaneous angiogenesis test.
    Rogala E; Skopińska-Rózewska E; Sommer E; Pastewka K; Chorostowska-Wynimko J; Sokolnicka I; Kazoń M
    Anticancer Res; 2001; 21(6B):4259-63. PubMed ID: 11908679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.
    Lamszus K; Jin L; Fuchs A; Shi E; Chowdhury S; Yao Y; Polverini PJ; Laterra J; Goldberg ID; Rosen EM
    Lab Invest; 1997 Mar; 76(3):339-53. PubMed ID: 9121117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiogenic factor: a possible mechanism for neovascularization produced by omental pedicles.
    Cartier R; Brunette I; Hashimoto K; Bourne WM; Schaff HV
    J Thorac Cardiovasc Surg; 1990 Feb; 99(2):264-8. PubMed ID: 1688990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Angiographic Structural Differentiation between Native Arteriogenesis and Therapeutic Synangiosis in Intracranial Arterial Steno-Occlusive Disease.
    Ooi YC; Laiwalla AN; Liou R; Gonzalez NR
    AJNR Am J Neuroradiol; 2016 Jun; 37(6):1086-91. PubMed ID: 26797139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angiogenic activity and neovascularization in adenocarcinoma of endometrium.
    Palczak R; Splawinski J
    Int J Gynaecol Obstet; 1989 Aug; 29(4):343-57. PubMed ID: 2477290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from moyamoya patients.
    Hitomi T; Habu T; Kobayashi H; Okuda H; Harada KH; Osafune K; Taura D; Sone M; Asaka I; Ameku T; Watanabe A; Kasahara T; Sudo T; Shiota F; Hashikata H; Takagi Y; Morito D; Miyamoto S; Nakao K; Koizumi A
    Biochem Biophys Res Commun; 2013 Aug; 438(1):13-9. PubMed ID: 23850618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathological Circulating Factors in Moyamoya Disease.
    Fang YC; Wei LF; Hu CJ; Tu YK
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of vascular endothelial growth factor in dura mater of patients with moyamoya disease.
    Sakamoto S; Kiura Y; Yamasaki F; Shibukawa M; Ohba S; Shrestha P; Sugiyama K; Kurisu K
    Neurosurg Rev; 2008 Jan; 31(1):77-81; discussion 81. PubMed ID: 17912564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Moyamoya disease in a patient with type I glycogenosis.
    Sunder TR
    Arch Neurol; 1981 Apr; 38(4):251-3. PubMed ID: 6938175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelial Progenitor Cells in Moyamoya Disease: Current Situation and Controversial Issues.
    Yu J; Du Q; Hu M; Zhang J; Chen J
    Cell Transplant; 2020; 29():963689720913259. PubMed ID: 32193953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proceedings: Adipose tissue fat cell size and number in relation to occlusion in the peripheral arteries.
    Harvey DR; Bliss BP
    Br J Surg; 1976 Feb; 63(2):156. PubMed ID: 1252743
    [No Abstract]   [Full Text] [Related]  

  • 34. Dural inversion for moyamoya disease.
    Scott RM
    J Neurosurg; 1998 Jan; 88(1):177-8. PubMed ID: 9420097
    [No Abstract]   [Full Text] [Related]  

  • 35. Metabolomic signatures associated with pathological angiogenesis in moyamoya disease.
    He S; Wang Y; Liu Z; Zhang J; Hao X; Wang X; Zhou Z; Wang R; Zhao Y
    Clin Transl Med; 2023 Dec; 13(12):e1492. PubMed ID: 38037492
    [No Abstract]   [Full Text] [Related]  

  • 36. Vascularization of composite auricular grafts transplanted to the chorio-allantois of the chick embryo.
    BALLANTYNE DL; CONVERSE JM
    Transplant Bull; 1958 Oct; 5(4):373-7. PubMed ID: 13592893
    [No Abstract]   [Full Text] [Related]  

  • 37. Insights into potential targeted nonsurgical therapies for the treatment of moyamoya disease.
    Goehner D; Kandregula S; Carroll CP; Zuccarello M; Guthikonda B; Kosty JA
    Neurosurg Focus; 2021 Sep; 51(3):E11. PubMed ID: 34469871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application of the chick embryo chorioallantoic membrane in neurosurgery disease.
    Yuan YJ; Xu K; Wu W; Luo Q; Yu JL
    Int J Med Sci; 2014; 11(12):1275-81. PubMed ID: 25419173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Angiogenic properties of various tissues utilized for synangiosis in moyamoya disease].
    Imaizumi T; Hashi K; Nakamura T; Tanabe S
    No Shinkei Geka; 1989 Jun; 17(6):515-20. PubMed ID: 2482453
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.